LENZ Therapeutics shares 3rd quarter financial results
LENZ Therapeutics, Inc. the pharmaceutical company focused on the commercialization of recently FDA-approved VIZZ (aceclidine ophthalmic solution) 1.44%, has announced financial results for the third quarter ending September 30, 2025, as well as recent corporate highlights. Highlighted among those was the FDA approval in late July of VIZZ, an aceclidine-based eye drop for the treatment…

